Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Genomic Revolution ETF (ARKG) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance

ARK Genomic Revolution ETF
Vanguard Information Technology Index Fund ETF

Price performance

Price movement over the last 24 hours

Key statistics

ARK Genomic Revolution ETF vs Vanguard Information Technology Index Fund ETF — how do they compare? ARK Genomic Revolution ETF trades at $41.21, while Vanguard Information Technology Index Fund ETF trades at $117. Which is the better fit depends on your goals.

ARKGVGT
Sector
Sector/Thematic
52-Week High
$43.57$125.77
52-Week Low
$23.09$83.59

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Genomic Revolution ETF

ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.

The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.

Vanguard Information Technology Index Fund ETF

VGT trades at $118.08, up 0.31% with a bullish technical signal from moving averages. The ETF shows strong institutional backing and positive media coverage highlighting its tech sector exposure and low 0.09% expense ratio. Recent news emphasizes VGT's outperformance versus QQQ and its role in AI-driven tech investments.

Outlook remains positive given tech sector momentum and AI growth catalysts, though risks include sector volatility and valuation concerns. Analyst sentiment favors VGT for broad tech diversification with competitive fees supporting long-term growth potential amid market fluctuations.

Returns comparison

Trailing returns across standard periods

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG

About Vanguard Information Technology Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.

Read more on VGT